Abstract:Domain-aware artificial intelligence has been increasingly adopted in recent years to expedite molecular design in various applications, including drug design and discovery. Recent advances in areas such as physics-informed machine learning and reasoning, software engineering, high-end hardware development, and computing infrastructures are providing opportunities to build scalable and explainable AI molecular discovery systems. This could improve a design hypothesis through feedback analysis, data integration that can provide a basis for the introduction of end-to-end automation for compound discovery and optimization, and enable more intelligent searches of chemical space. Several state-of-the-art ML architectures are predominantly and independently used for predicting the properties of small molecules, their high throughput synthesis, and screening, iteratively identifying and optimizing lead therapeutic candidates. However, such deep learning and ML approaches also raise considerable conceptual, technical, scalability, and end-to-end error quantification challenges, as well as skepticism about the current AI hype to build automated tools. To this end, synergistically and intelligently using these individual components along with robust quantum physics-based molecular representation and data generation tools in a closed-loop holds enormous promise for accelerated therapeutic design to critically analyze the opportunities and challenges for their more widespread application. This article aims to identify the most recent technology and breakthrough achieved by each of the components and discusses how such autonomous AI and ML workflows can be integrated to radically accelerate the protein target or disease model-based probe design that can be iteratively validated experimentally. Taken together, this could significantly reduce the timeline for end-to-end therapeutic discovery and optimization upon the arrival of any novel zoonotic transmission event. Our article serves as a guide for medicinal, computational chemistry and biology, analytical chemistry, and the ML community to practice autonomous molecular design in precision medicine and drug discovery.

Artificial Intelligence-Guided Strategies for Next-Generation Biological Sequence Design

Can AI design life?

Designing Biological Sequences Without Prior Knowledge Using Evolutionary Reinforcement Learning

Artificial Intelligence in Genomic Sequence, Protein Structure Function Prediction and DNA Microarrays: a Survey

Generative AI for Controllable Protein Sequence Design: A Survey

[De Novo Protein Design in the Age of Artificial Intelligence].

[Bioinformatics] Artificial Intelligence Learns Protein Prediction

Artificial Intelligence for Autonomous Molecular Design: A Perspective

From sequence to function through structure: deep learning for protein design

Revolutionizing enzyme engineering through artificial intelligence and machine learning

Revolutionizing Molecular Design for Innovative Therapeutic Applications through Artificial Intelligence

[Progress in the application of artificial intelligence-assisted molecular modification of enzymes]

Generative artificial intelligence for de novo protein design

Automated Biodesign Engineering by Abductive Meta-Interpretive Learning

AI: A transformative opportunity in cell biology

Harnessing generative AI to decode enzyme catalysis and evolution for enhanced engineering

AI-Assisted Rational Design and Activity Prediction of Biological Elements for Optimizing Transcription-Factor-Based Biosensors

Toward AI-Driven Digital Organism: Multiscale Foundation Models for Predicting, Simulating and Programming Biology at All Levels

Artificial intelligence-driven biomedical genomics

Advancing microbial production through artificial intelligence-aided biology